| Smart Vision, Llc | |
|
255 Western Ave, Augusta, ME 04330-4933 | |
| (207) 622-5800 | |
| (207) 621-2790 |
| Full Name | Smart Vision, Llc |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 255 Western Ave, Augusta, Maine |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043394885 | NPI | - | NPPES |
| 125420101 | Medicaid | ME | |
| 125420001 | Medicaid | ME | |
| 125420100 | Medicaid | ME |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | OPT961 (Maine) | Primary |
| 332H00000X | Eyewear Supplier | (* (Not Available)) | Secondary |
| Provider Name | Sarah J Gladstone |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1285829333 PECOS PAC ID: 2668560590 Enrollment ID: I20071110000049 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Laura K Dowd |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1255567467 PECOS PAC ID: 0648310789 Enrollment ID: I20091221000430 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | James S Brewer |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1336403286 PECOS PAC ID: 6507016268 Enrollment ID: I20121016000176 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Lucie Neron |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1568701555 PECOS PAC ID: 3971749870 Enrollment ID: I20130419000436 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Ethan R Taylor |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1306272406 PECOS PAC ID: 8820309586 Enrollment ID: I20150622001585 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Jessilin M Quint |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1841603867 PECOS PAC ID: 2062639693 Enrollment ID: I20150708001910 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Nicholas A Holden |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1366891434 PECOS PAC ID: 7113290073 Enrollment ID: I20170829002362 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Provider Name | Anne Tobyne |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1821478371 PECOS PAC ID: 7315204435 Enrollment ID: I20180821001248 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Smart Vision, Llc 255 Western Ave, Augusta, ME 04330-4933 Ph: (207) 622-5800 | Smart Vision, Llc 255 Western Ave, Augusta, ME 04330-4933 Ph: (207) 622-5800 |
News Archive
USANA Health Sciences, Inc. today announced record financial results for its fiscal second quarter ended July 3, 2010.
Politico Pro reports that if power shifts to the right the implementation of the health law could be minimized.
K2M, Inc., a spinal device company developing innovative solutions for the treatment of complex spinal pathologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its new CHESAPEAKE™ Anterior-Lumbar Stabilization System, a unique interbody device designed for stabilization of the spine through an anterior approach. The system provides screw fixation through K2M's revolutionary tifix® Locking Technology, whereby each screw head forms an autogenic lock to the implant upon insertion.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Research by Bangor University's Professor Dyfrig Hughes has provided important evidence on the safety of treatments that are being tested for use in COVID-19.
› Verified 6 days ago
Dr. James P Smith, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1 Va Ctr, Togus Vamc Eye Clinic, Augusta, ME 04330 Phone: 207-623-8411 | |
Benjamin I Graham, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 1 Va Ctr, Augusta, ME 04330 Phone: 207-623-8411 | |
Hannah Michaella Wood, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1 Va Center, Surgical Service 112 E, Augusta, ME 04330 Phone: 207-623-8411 | |
Dr. Stephanie Lynn Arnio, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1 Va Ctr, Augusta, ME 04330 Phone: 207-623-8411 | |
Advanced Vision Care Of Maine Optometrist Medicare: Medicare Enrolled Practice Location: 254 Western Ave, Augusta, ME 04330 Phone: 207-622-3015 Fax: 207-621-7716 | |
Dr. Leah D Grotton, O.D Optometrist Medicare: Accepting Medicare Assignments Practice Location: 58 State St, Augusta, ME 04330 Phone: 207-623-5099 Fax: 207-623-7124 |